Neoadjuvant Botensilimab (BOT) plus Balstilimab (BAL) in Resectable Stage III Microsatellite Stable (MSS) Colorectal Cancer



Pretreatment
MSS Sigmoid Tumor

Week 7
After 1 dose BOT + 2 doses BAL
Patient achieved CR

BAL, balstilimab; BOT, botensilimab; MSS, microsatellite stable, CR, Complete Response. 1. Kasi P, et al. Oral presentation at the ESMO Gastrointestinal Cancers Congress. Munich, Germany 2024. Presentation #743. 2. Chalabi M, et al. Oral presentation at AACR. Chicago, IL, USA 2025. Abstract #CT130.